+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Survival Motor Neuron Protein"

Europe Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type (Type 1, Type 2, Type 3 and Type 4), By Route of Administration, By Treatment Type (Drug and Gene Therapy), By Drug Type, By Country and Growth Forecast, 2022 - 2028 - Product Thumbnail Image

Europe Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type (Type 1, Type 2, Type 3 and Type 4), By Route of Administration, By Treatment Type (Drug and Gene Therapy), By Drug Type, By Country and Growth Forecast, 2022 - 2028

  • Report
  • November 2022
  • 98 Pages
  • Europe
From
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 83 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Survival Motor Neuron Protein (SMN) market is a subset of the Central Nervous System (CNS) drugs market. SMN is a protein that is essential for the development and maintenance of motor neurons, which are responsible for controlling voluntary muscle movement. Deficiencies in SMN protein can lead to a range of neuromuscular disorders, including spinal muscular atrophy (SMA). As a result, SMN-targeting drugs are being developed to treat SMA and other neuromuscular disorders. The SMN market is expected to grow rapidly in the coming years, driven by the increasing prevalence of SMA and other neuromuscular disorders, as well as the development of new SMN-targeting drugs. Companies in the SMN market include Biogen, Novartis, AveXis, and PTC Therapeutics. Show Less Read more